Yuji Koga

This inventor holds 17 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Astellas Pharma Gmbh, Denka Company Limited, Yamanouchi Pharmaceutical Company Ltd.. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuji Koga. Retrieved from https://idiyas.com/inventor/yuji-koga-y0m9ye2c

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 29.4

CIPO Patents = 1

EPO Patents = 10 (Patent Applications = 5)

Average Co-Inventor Count = 8.5

ph-index = 5

Forward Citations = 49(Granted Patents)

Location History:

Chuo-ku, JP (2009 - 2011)
Tsukuba, JP (2003 - 2012)
Tokyo, JP (2008 - 2016)

Company Filing History:

Denka Company Limited

patents

1 out of 329

Yamanouchi Pharmaceutical Company Ltd.

patents

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Carbon Black

Lithium-Ion Battery

Imidazopyridine

Glycine

Acylaminothiazole

Quinolone

Benzene Derivatives

Diazepan

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12700594 - Carbon black, slurry, and lithium-ion secondary battery (2026-08-04),

2. 9447090 - Imidazopyridine compounds (2016-09-20),

3. 9278968 - Imidazopyridine compounds (2016-03-08),

4. 8802679 - Glycine compound (2014-08-12),

5. 8765764 - 2-acylaminothiazole derivative or salt thereof (2014-07-01),

6. 8629126 - Quinolone derivative or pharmaceutically acceptable salt thereof (2014-01-14),

7. 8338429 - 2-acylaminothiazole derivative or salt thereof (2012-12-25),

8. RE43481 - Diazepan derivatives or salts thereof (2012-06-18),

9. 8133882 - Quinolone derivative or pharmaceutically acceptable salt thereof (2012-03-13),

10. 7879878 - Quinolone derivative or salt thereof (2011-02-01),

11. 7786106 - Substituted benzene derivatives or salts thereof (2010-08-31),

12. 7638536 - 2-Acylaminothiazole derivative or salt thereof (2009-12-29),

13. 7504417 - Substituted benzene derivatives or salts thereof (2009-03-17),

14. 7488739 - Quinolone derivative or salt thereof (2009-02-10),

15. 7361658 - 2-acylaminothiazole derivative or salt thereof (2008-04-22),

Title: Yuji Koga - Pioneering Innovator in Cardiovascular Pharmaceutical Development

Introduction

Yuji Koga is an esteemed inventor based in Tokyo, Japan. With an impressive portfolio of 16 patents, he has made significant contributions to the field of cardiovascular medicine through his innovative research and development in pharmaceutical compounds.

Latest Patents

Koga's latest inventions include imidazopyridine compounds that are designed for treating or preventing cardiovascular diseases. One notable patent details a drug that enhances cGMP production via soluble guanylate cyclase activation. The compounds exhibit a unique structure, featuring a carbamoyl group at the 3-position and a substituent bonded at the 8-position through an oxygen atom in the imidazo[1,2-a]pyridine skeleton. This discovery positions these compounds as valuable therapies for various soluble guanylate cyclase-related cardiovascular conditions.

Another patent addresses pharmaceutical compositions aimed at improving cGMP signals to manage cardiovascular diseases. Koga identified imidazo[1,2-a]pyridine compounds with a specific cyclic group that enhances sGC activation. These inventions are particularly useful for treating peripheral arterial diseases, hypertension, and pulmonary hypertension, showcasing Koga’s commitment to advancing cardiovascular health.

Career Highlights

Throughout his career, Yuji Koga has worked with prominent pharmaceutical companies, including Astellas Pharma and Yamanouchi Pharmaceutical Company Ltd. His work at these institutions has significantly advanced drug development and has impacted the treatment of various cardiovascular conditions.

Collaborations

Koga has collaborated with esteemed colleagues such as Fukushi Hirayama and Keizo Sugasawa. These partnerships have played a crucial role in pooling expertise and fostering innovation in cardiovascular drug research.

Conclusion

Yuji Koga stands out as a leading inventor in the realm of cardiovascular pharmaceuticals. His innovative imidazopyridine compounds hold the promise of transforming treatment approaches for cardiovascular diseases, demonstrating his dedication to enhancing health outcomes through scientific advancement.

Profile summary based on public USPTO records.